NASDAQ:BLTE 11 December 2025 - 30 December 2025

Belite Bio, Inc. has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range.BioPharma Dive+1 As of the afternoon of December 11, 2025, Belite Bio stock is trading around $154 per share, up roughly 4–5% on the day and more than 130% year‑to‑date, giving the company a market capitalization of roughly $5–6 billion.Stock Titan+1 The rally has pushed BLTE to the upper end of its 52‑week range of about $53 to $154, but Wall Street price targets and recent valuations suggest many analysts still see meaningful upside.